Quick Answer
10x Genomics, Inc. reported Stockholders Equity of $796.33 million for the year ending 2025.
- 10x Genomics, Inc. showed an increase of +12.1% in Stockholders Equity from 2024 to 2025.
- This data is from 10x Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$127.25 million | Q2 2018: -$132.47 million | Q3 2018: -$146.77 million | Q1 2019: -$221.29 million | Q2 2019: -$227.95 million | Q3 2019: $421.45 million | Q1 2020: $409.07 million | Q2 2020: $391.27 million | Q3 2020: $825.08 million | Q1 2021: $752.46 million | Q2 2021: $784.59 million | Q3 2021: $800.22 million | Q1 2022: $806.69 million | Q2 2022: $783.52 million | Q3 2022: $775.79 million | Q1 2023: $802.39 million | Q2 2023: $793.30 million | Q3 2023: $745.22 million | Q1 2024: $718.83 million | Q2 2024: $724.06 million | Q3 2024: $722.80 million | Q1 2025: $706.90 million | Q2 2025: $773.28 million | Q3 2025: $785.12 million.
- Over the full 10 years of available data (2016 to 2025), 10x Genomics, Inc.'s Stockholders Equity has grown by 925.8%.
- Historical annual values: Fiscal year 2025: $796.33 million | Fiscal year 2024: $710.13 million | Fiscal year 2023: $741.04 million | Fiscal year 2022: $805.74 million | Fiscal year 2021: $817.57 million | Fiscal year 2020: $739.07 million | Fiscal year 2019: $420.08 million | Fiscal year 2018: -$219.99 million | Fiscal year 2017: -$112.51 million | Fiscal year 2016: -$96.43 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: